TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15243283
Drug: Intranasal 17beta-estradiol
Normalized name: Estradiol-17beta
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal 17beta-estradiol 300 microg/day plus nomegestrole acetate 5 mg/day for 12 days per 28-day cycle for 6 months (Group B)
Study: 20368220
Drug: Simvastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (40 mg, daily)
Study: 7988349
Drug: No drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: No drugs (control group A)
Study: 11196741
Drug: Commercially available
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Commercially available MMR vaccine (MMR-II, Merck)
Study: 10660867
Drug: Caffeine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (5 mg.kg-1)
Study: 30566712
Drug: Intraoperative PFC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative PFC injection
Study: 30566712
Drug: No PFC
Approvals — FDA: no, EMA: no, PMDA: no
Description: No PFC injection (Control)
Study: 27491822
Drug: Measurement of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Measurement of the blood level of the biomarker soluble urokinase plasminogen activator receptor (suPAR) within 2 hours after admission, with immediate reporting to treating physicians in the ED.
Study: 18373577
Drug: Tailored daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailored daily messages via cellphone prompting to enhance diabetic self-care behaviour
Study: 16078923
Drug: Apheresis platelets
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apheresis platelets treated with riboflavin (500 micromol per L) and UV light (6.2 J per mL)
Study: 10915328
Drug: Hierarchical grading
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hierarchical grading systems (e.g., grades I, II, and III)
Study: 26964157
Drug: Western medication
Normalized name: Western wheatgrass
DrugBank: Pascopyrum smithii pollen (DB10719)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medication (cetirizine hydrochloride)
Study: 21300334
Drug: GnRH antagonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH antagonist administered from day 2 of the menstrual cycle for 3 consecutive days, followed by standard treatment with daily injections of recombinant FSH (rFSH) starting on day 2 of the cycle at a dose of 150-225 IU/day, and GnRH antagonists from cycle day 7 onward.
Study: 21300334
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment with daily injections of recombinant FSH (rFSH) starting on day 2 of the cycle at a dose of 150-225 IU/day, and GnRH antagonists from cycle day 7 onward.
Study: 7804974
Drug: Placebo of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo of live vaccinia vaccine virus (V), 10(5.4) TCID50/ml, administered once a week for 13 weeks and then once every 2 weeks for an additional 39 weeks
Study: 8646509
Drug: Placebo of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo of live vaccinia vaccine virus (V)
Study: 30561729
Drug: High hemoglobin
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High hemoglobin group (12.5-13.5 g/dL)
Study: 30561729
Drug: Low hemoglobin
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low hemoglobin group (10.5-11.5 g/dL)
Study: 29504369
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy (SLIT) with high dose Dermatophagoides farinae
Study: 26576716
Drug: Autonomic Regulation
Normalized name: AUTONOMIC MEDICATIONS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autonomic Regulation Therapy (ART) via vagus nerve stimulation (VNS)
Study: 23985355
Drug: Group music
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group music therapy, no restrictions on frequency, duration, or contents.
Study: 20104222
Drug: Sunitinib 50
Normalized name: sunitinib 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib 50 mg per day in 6-week cycles (4 weeks on, 2 weeks off treatment)
Study: 12008859
Drug: Etanercept 25
Normalized name: etanercept 25 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept 25 mg subcutaneously twice weekly
Study: 16128597
Drug: Colestilan (four
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colestilan (four tablets administered in divided doses with three glasses of water before dinner and bedtime for 12 weeks)
Study: 6986746
Drug: Combined group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined group of patients with 3 or more and 4 or more hours of treatment
Study: 31358408
Drug: 3-dose vaccination
Normalized name: hepatitis A vaccine, pediatric/adolescent dosage, 3 dose schedule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-dose vaccination (3D) at 7-day post-booster
Study: 26626341
Drug: Hospital-based Direct
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hospital-based Direct Observation of Treatment (HBDOT)
Study: 22872005
Drug: G-CSF (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF (10 μg/kg/day for 3 consecutive days with an additional half-dose 4 hours before surgery)
Study: 15516942
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no G-CSF)
Study: 21455076
Drug: Infrapatellar nerve
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infrapatellar nerve block (IPNB; 10 ml levobupivacaine 0.5%)
Study: 1512807
Drug: Matching clients
Normalized name: By Ache
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching clients to alternative treatment strategies; specific strategies not detailed.
Study: 6747752
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose (0.5 ml) DTP vaccine
Study: 6747752
Drug: Modified dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified dose (0.25 ml) DTP vaccine
Study: 30045425
Drug: Snack containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Snack containing green leafy vegetables, fruit, and milk (mean 54.1 mg ALA)
Study: 30045425
Drug: Control snack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control snack containing low micronutrient foods (mean 4.1 mg ALA)
Study: 10862807
Drug: Daily buprenorphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily buprenorphine (16 mg/70 kg)
Study: 10862807
Drug: Thrice-weekly buprenorphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrice-weekly buprenorphine (34 mg/70 kg on Fridays and Sundays, 44 mg/70 kg on Tuesdays)
Study: 374194
Drug: Control preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control preparation
Study: 3351689
Drug: Theophylline plus
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Theophylline plus diuretics
Study: 26209163
Drug: Circumferential topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Circumferential topical anesthetic blockade of skin surrounding the wrist
Study: 30056355
Drug: Intramyometrial vasopressin
Normalized name: Vasopressin
DrugBank: Vasopressin (DB00067)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramyometrial vasopressin plus rectal misoprostol (30 min before procedure)
Study: 24700631
Drug: Strength training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strength training group (19 boys, 22 girls) training twice a week for 8 weeks
Study: 24700631
Drug: Endurance training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endurance training group (21 boys, 24 girls) training twice a week for 8 weeks
Study: 7668039
Drug: WC/rBS cholera
Approvals — FDA: no, EMA: no, PMDA: no
Description: WC/rBS cholera vaccine
Study: 8267992
Drug: Intravenous magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous magnesium chloride (50 mmol)
Study: 4055163
Drug: Paracetamol +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol + l‐methionine (5:1)
Study: 4055163
Drug: Paracetamol (1,500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol (1,500 mg)
Study: 24655552
Drug: Transdermal HRT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal HRT (50μg/day estradiol alone for days 1-14 and 50μg/day estradiol plus 0.25mg/day norethisterone acetate for days 15-28 for 6 months)
Study: 24655552
Drug: Both oral
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both oral and transdermal HRT
Study: 19657689
Drug: 6-month subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-month subcutaneous denosumab injection (60 mg) plus weekly oral placebo
Study: 19657689
Drug: Weekly alendronate
Normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly alendronate tablet (70 mg) plus 6-month subcutaneous placebo injection
Study: 7547154
Drug: Intensive medication
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive medication counselling for 3 months
Study: 31806533
Drug: Vaccine Information
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine Information Statements (VIS) only
Study: 25854020
Drug: Integrated therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated therapy of acupuncture and pingganjianpi decoction
Study: 25854020
Drug: Haloperidol tablets
Normalized name: Haloperidol Tablets
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Haloperidol tablets (0.05 mg/kg per day, twice a day for 30 days)
Study: 11709334
Drug: Gemifloxacin 320
Normalized name: gemifloxacin 320 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemifloxacin 320 mg
Study: 9758289
Drug: Trovafloxacin 200
Normalized name: trovafloxacin 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trovafloxacin 200 mg
Study: 9626153
Drug: 0.6 IU/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 IU/day recombinant human growth hormone (rhGH)
Study: 9626153
Drug: 1.2 IU/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.2 IU/day recombinant human growth hormone (rhGH)
Study: 9626153
Drug: 1.8 IU/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.8 IU/day recombinant human growth hormone (rhGH)
Study: 7897380
Drug: Combined hepatitis
Normalized name: hepatitis nosodes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined hepatitis A (720 ELISA units) and hepatitis B (20 micrograms) vaccine
Study: 30317290
Drug: 1gm acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1gm acetaminophen
Study: 28962596
Drug: Chiropractic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chiropractic treatment individualized to each woman
Study: 23216412
Drug: Celecoxib 100
Normalized name: celecoxib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib 100 mg b.d.
Study: 23216412
Drug: Loxoprofen 60
Normalized name: loxoprofen 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loxoprofen 60 mg t.d.s.
Study: 20864893
Drug: 0.3 mg
Normalized name: biotin 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg flumazenil
Study: 11424245
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose N‐9 products
Study: 2649213
Drug: 0.05% clobetasol-17-propionate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05% clobetasol-17-propionate cream
Study: 19272659
Drug: Incremental acetylcholine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Incremental acetylcholine (Ach; 20, 50 and 100 microg/min) infusion
Study: 17008536
Drug: Granulocyte colony-stimulating
Normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granulocyte colony-stimulating factor (G-CSF) after inductions 1 and 2
Study: 7543781
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no G-CSF)
Study: 17008536
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (G-CSF and control)
Study: 26419871
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment with SSGs
Study: 26419871
Drug: SSGs in
Approvals — FDA: no, EMA: no, PMDA: no
Description: SSGs in combination with cultured autologous epidermal cells (ECs)
Study: 24626433
Drug: Simvastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (20 mg) plus Ezetimibe (10 mg) daily
Study: 24626433
Drug: Any LDL-C-lowering
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any LDL-C-lowering therapy
Study: 19761983
Drug: Creatinine increase
Normalized name: Creatinine
DrugBank: Creatinine (DB11846)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatinine increase (for a 10-mumol/l increase)
Study: 17209666
Drug: Lercanidipine/enalapril 10mg/20mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lercanidipine/enalapril 10mg/20mg once daily
Study: 31172172
Drug: Whole eggs
Normalized name: EGG
DrugBank: Egg (DB10529)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole eggs (100 g, ∼2 whole eggs per day)
Study: 31172172
Drug: Yolk-free eggs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yolk-free eggs (100 g, ∼2 yolk-free eggs per day)
Study: 22086091
Drug: Transforaminal (TF)
Normalized name: transforming growth factor beta 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transforaminal (TF) epidural steroids
Study: 22086091
Drug: Interlaminar (IL)
Normalized name: Ile
DrugBank: Isoleucine (DB00167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interlaminar (IL) epidural steroids
Study: 18435479
Drug: Menthol inhalation
Normalized name: Eucalyptus/Menthol Inhalation Pad
Approvals — FDA: no, EMA: no, PMDA: no
Description: Menthol inhalation
Study: 9863113
Drug: Q-wave millimeter
Normalized name: Chew Q
Approvals — FDA: no, EMA: no, PMDA: no
Description: Q-wave millimeter microwave (QWMM) irradiation starting 10 days after operation and combined with chemotherapy on the 16th day (Group A)
Study: 9863113
Drug: Q-wave millimeter
Normalized name: Chew Q
Approvals — FDA: no, EMA: no, PMDA: no
Description: Q-wave millimeter microwave (QWMM) irradiation starting immediately after chemotherapy induced peripheral WBC reduction (Group B)
Study: 8347733
Drug: 10 micrograms/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 micrograms/kg body wt. daily s.c. GM-CSF
Study: 2939636
Drug: prednicarbate 0.25%
Approvals — FDA: no, EMA: no, PMDA: no
Description: prednicarbate 0.25% in emulsifiable greasy ointment without water
Study: 2939636
Drug: prednicarbate 0.25%
Approvals — FDA: no, EMA: no, PMDA: no
Description: prednicarbate 0.25% in w/o emulsion (ointment)
Study: 2939636
Drug: prednicarbate 0.25%
Approvals — FDA: no, EMA: no, PMDA: no
Description: prednicarbate 0.25% in o/w emulsion (cream)
Study: 29705445
Drug: Bitter orange
Normalized name: BITTER ORANGE
DrugBank: Citrus aurantium fruit (DB16598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bitter orange (500 mg capsules)
Study: 29705445
Drug: Lavender (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lavender (500 mg capsules)
Study: 20054280
Drug: Corrected C/G
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corrected C/G ratio
Study: 9745969
Drug: Ephedrine hydrochloride
Normalized name: Ephedrine Hydrochloride
DrugBank: Ephedrine (DB01364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ephedrine hydrochloride tablets after lunch and before bedtime for 2 months
Study: 9745969
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group treatments (imipramine hydrochloride, desmoporessin, ritaline, cetiprin, or behavioral therapy)
Study: 22348233
Drug: Indomethacin (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (0.1 mg/kg)
Study: 30600137
Drug: Exenatide once
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exenatide once weekly (QW) 2 mg
Study: 25535318
Drug: Acceptance and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acceptance and Commitment Therapy (ACT) workshop plus behavioral family intervention (BFI)
Study: 23235135
Drug: Early surfactant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early surfactant administration (n = 74)
Study: 16781986
Drug: Home administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Home administration of intravenous methylprednisolone
Study: 16781986
Drug: Outpatient administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Outpatient administration of intravenous methylprednisolone
Study: 11994701
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of zafirlukast and loratadine
Study: 31849027
Drug: Buprenorphine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine (4 or 6 mg/d)
Study: 22480818
Drug: Escitalopram 10
Normalized name: escitalopram 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram 10 mg/d
Study: 22480818
Drug: Escitalopram 20
Normalized name: escitalopram 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram 20 mg/d (after week 4 for non-responders)
Study: 12966478
Drug: Parecoxib sodium
Normalized name: parecoxib sodium
DrugBank: Parecoxib (DB08439)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Parecoxib sodium 20 to 100 mg
Study: 12966478
Drug: Parecoxib sodium
Normalized name: parecoxib sodium
DrugBank: Parecoxib (DB08439)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Parecoxib sodium <20 mg
Study: 8800985
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose dobutamine (5-10 micrograms/kg/min over 5 min)
Study: 8800985
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose dobutamine (20-40 micrograms/kg/min over 3 min)
Study: 6549194
Drug: Control (before
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (before calcitriol administration) with dietary intake of 9.3 mmoles Ca/day
Study: 29783095
Drug: Buprenorphine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine treatment initiated prior to release
Study: 29783095
Drug: Buprenorphine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine treatment initiated after release
Study: 27430210
Drug: Fibrinogen concentrate
Normalized name: Fibrinogen concentrate human
DrugBank: Fibrinogen human (DB09222)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrinogen concentrate (Riastap®) 60-70 mg/kg
Study: 25164471
Drug: Supervised physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised physical therapy (3 sessions/week for 24 weeks)
Study: 15805342
Drug: Nicotine patch
Normalized name: Nicotine Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine patch (21 mg)
Study: 17451401
Drug: Nalmefene 10
Normalized name: nalmefene 100 MCG in 1 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nalmefene 10 to 40 mg
Study: 11800375
Drug: Lidocaine-adrenaline solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine-adrenaline solution (LA)
Study: 8133114
Drug: Primaquine (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primaquine (0.25 mg of base/kg of body weight/day over 14 days)
Study: 8133114
Drug: Chloroquine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloroquine (25 mg of base/kg over 3 days)
Study: 2550245
Drug: Insulin 0.125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin 0.125 U.kg-1 + placebo
Study: 2550245
Drug: Insulin +
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin + hANP
Study: 789791
Drug: Conventional A/England/42/72
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional A/England/42/72 (H3N2) vaccine (X‐37)
Study: 789791
Drug: Antigenic hybrid
Normalized name: TRICOPHYTON ANTIGEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antigenic hybrid (Heq1N2) vaccine (X‐38)
Study: 22167767
Drug: N(2)-L-alanyl-L-glutamine (GLN)
Normalized name: N(2)-L-Alanyl-L-glutamine
DrugBank: Alanyl glutamine (DB11876)
Approvals — FDA: no, EMA: no, PMDA: no
Description: N(2)-L-alanyl-L-glutamine (GLN) 0.4 g/kg per day
Study: 16377979
Drug: Ribose supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ribose supplementation (10 g in 8 oz water)
Study: 16377979
Drug: Dextrose supplementation
Normalized name: Dextrose
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextrose supplementation (10 g in 8 oz water)
Study: 15054512
Drug: Cariporide 120
Normalized name: Cariporide
DrugBank: Cariporide (DB06468)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cariporide 120 mg
Study: 3777409
Drug: Nalbuphine 20
Normalized name: nalbuphine 20 mg/mL injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nalbuphine 20 mg
Study: 30376537
Drug: Low-dose ketamine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose ketamine (LDK) at 2.5 μg·kg·min for 48 hours
Study: 30471966
Drug: Conventional aquatic
Normalized name: Mentha aquatica leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional aquatic therapy (50min)
Study: 25459890
Drug: Isoallopregnanolone (ISO)
Normalized name: iso-sulfan blue
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoallopregnanolone (ISO) administered in combination with Allopregnanolone (AP)
Study: 18633421
Drug: Maternal massage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maternal massage therapy (standard care plus maternal massage performed four times a day on the face and limbs)
Study: 18633421
Drug: Maternal massage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maternal massage therapy
Study: 11309871
Drug: 0.3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg/kg intra-nasal midazolam
Study: 11309871
Drug: 0.4 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg/kg intra-nasal midazolam
Study: 11309871
Drug: 0.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/kg intra-nasal midazolam
Study: 9361167
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg once daily (OM20)
Study: 9361167
Drug: Omeprazole 10
Normalized name: omeprazole 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 10 mg once daily (OM10)
Study: 31060106
Drug: Activities of
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activities of Daily Living (ADL) I (without disability)